Treating Hormone Receptor-Positive Breast Cancer: A Brave New World

ACPE UAN #:  0233-0000-16-051-H01-P 

Release Date: December 20, 2016

Expiration Date:  October 5, 2019

Activity Type:    Knowledge-based

Contact Hours:  1.5

Activity Fee:  Member:  Free        Non-Member: $30

Target Audience: Pharmacists who practice in managed care settings.

Activity Overview

The introduction of the cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor palbociclib heralded another revolution in the treatment of metastatic, hormone receptor-positive, HER2- negative breast cancer. Results of clinical trials prompted major guideline revisions, putting the sequencing of agents in flux and complicating utilization management reviews in this care setting. At the same time, excitement about the dramatic improvements in progression-free survival associated with this new class of oral medications has been tempered by concerns related to safety, drug interactions and adherence. 

This session explores the current status and evidence for the use of CDK4/6 inhibitors. Treatment guidelines and recommendations will be discussed in context of new and emerging data, and practical strategies for adjusting doses and promoting adherence will be reviewed. The session will conclude with an in-depth look at the CDK4/6 pipeline and how the treatment landscape will continue to evolve as new agents are introduced. 

Learning Objectives:  

At the completion of this activity, participants should be able to:

  1. Define the role of CDK4/6 inhibitors in the treatment of breast cancer, based on currently available evidence.
  2. Describe utilization management strategies and dosage adjustment recommendations for CDK4/6 inhibitors based on toxicity or drug interactions.
  3. Discuss emerging information about the currently marketed CDK4/6 inhibitor as well as investigational agents likely to be approved in the next few years. 

Schedule of Educational Activity

This activity consists of an audio recording, pre-test assessment questions (not required to pass or continue), post-test questions (required to pass with a score of 70% or higher) and a specific activity evaluation. 

CPE Requirements:   

Participants should claim continuing pharmacy education (CPE) credit for this home study activity only if they have not claimed credit for the live activity presented at AMCP Nexus 2016. 

CPE credit will be processed through the AMCP Learn portal and reported directly to CPE Monitor.  Please allow 72 hours for processing and posting in your NABP account.

To receive credit for an online activity you must:

  • Review the full content of the activity.
  • Successfully complete the post-test (required to pass with a score of 70% or higher, it may be taken a maximum of three times).
  • Complete a specific activity evaluation.


As an accredited provider, AMCP strictly adheres to the ACPE Standards for Commercial Support and other relevant guidelines and standards to ensure the independence of continuing pharmacy education (CPE) activities.  It is AMCP’s intent that all CPE activities be independent, objective, balanced, evidence-based and free of any commercial bias.

System Technical Requirements/Viewing Requirements: System Requirements Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities you should have a basic comfort level using a computer and navigating web sites.  View the minimum technical and system requirements for continuing education online learning activities.


Rachel Anhorn, PharmD
Director, Payer Medical Affairs Foundation Medicine
Cambridge, Massachusetts

Credit Information

Activity Number Credit Amount Accreditation Period
ACPE UAN #0233-0000-16-051-H01-P 1.5 Contact Hours October 05, 2016 - October 05, 2019